Microsalt PLC

Management Reports • Jun 27, 2025

National Storage Mechanism | Additional information

RNS Number : 8240O

MicroSalt PLC

27 June 2025

27 June 2025

MicroSalt Plc

("MicroSalt" or the "Company")

Result of AGM

MicroSalt plc, a leading manufacturer of full flavour salt with approximately 50% less sodium is pleased to announce that all resolutions proposed to shareholders at its Annual General Meeting today were duly passed.

The total number of votes received in respect of all resolutions were as follows:

	For			Against		Votes Withheld	Total votes cast
Number of Votes	%		Number of Votes	%
Ordinary Resolutions
1. Approval of Annual Report and Accounts	34,823,571	99.96		15,264	0.04	103	34,838,835
2. To re-appointment Crowe U.K. LLP as Auditors	34,822,719	99.95		15,852	0.05	367	34,838,571
3. To authorise Directors to set Auditors remuneration	34,822,744	99.95		16,091	0.05	103	34,838,835
6. To re-elect Judith Batchelar as a Director	34,813,092	99.94		19,163	0.06	6,683	34,832,255
4. To re-elect Rick Guiney as a Director	34,819,303	99.94		19,163	0.06	472	34,838,466
5. To re-elect Konrad Dabrowski as a Director	34,818,715	99.94		19,751	0.06	472	34,838,466
7. To re-elect Gary Urmston as a Director	34,820,032	99.95		18,434	0.05	472	34,838,466
8. To re-elect Daniel Emery as a Director	34,821,246	99.95		17,220	0.05	472	34,838,466
9. Authority to Allot Shares	34,783,598	99.95		18,034	0.05	37,306	34,801,632
Special Resolution
10. Disapplication of pre-emption rights	34,788,116	99.94	19,358		0.06	31,464	34,807,474

Notes:

1.   Proxy appointments which gave discretion to the Chairman of the AGM have been included in the "For" total for the appropriate resolution.

2.   Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution.

3.   A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against".

4.   The number of shares in issue on 27 June 2025 was 51,963,276.

5.   The full text of the resolutions passed at the AGM can be found in the Notice of Annual General Meeting which is available on the Company's website at www.microsalt.co.

For further information, please visit MicroSalt's website or contact:

MicroSalt plc	Via Flagstaff PR
Rick Guiney, CEO
Zeus (Nominated Adviser and Broker)	+44 (0)20 3829 5000
David Foreman / James Edis (Investment Banking)
Dom King (Corporate Broking), Rupert Woolfenden (Sales)
Flagstaff PR (Financial PR/IR)	+44 (0)20 7129 1474
Tim Thompson / Alison Allfrey / Anna Probert

Notes to Editors

MicroSalt® produces a patented full-flavour, low-sodium salt for food manufacturers and consumers.

MicroSalt is a major potential disruptor in the food market, thanks to its micron sized particles which deliver the same sense of saltiness to a wide range of foods but with approximately 50% less sodium. Excess sodium consumption is a significant contributor to cardiovascular disease and MicroSalt's solution meets the rising demand for healthier alternatives to traditional salt. The WHO has set a target for reducing global sodium intake by 30% by 2025, which it estimates will save 7 million lives by 2030.

Each year, cardiovascular disease costs the UK £19 billion - if the average salt intake was reduced by one gram per day, it has been estimated that 4,147 lives and £288 million would be saved each year in the UK. As a nation, the UK consumes 183 million kilograms of salt each year, and 70 per cent. of the typical person's sodium intake is hidden in processed foods.

Operational since 2018, MicroSalt uses a patent-protected technology which helps create high barriers to entry within the reduced-sodium salt market. The group has a US patent and 14 patent applications pending in other jurisdictions globally.

The Directors believe that MicroSalt is well positioned to capture growth in the low sodium market, which is expected to grow exponentially, and that there is also scope to enter the larger salt market.

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGDZGZVDNVGKZM